Fig. 4

Phospho-sites identified in proteins of the RAS-RAF-MAPK and PI3K-AKT signaling pathway in a lung adenocarcinoma cell line harboring a L858R mutation in the kinase domain of EGFR, which is reactive to treatment with erlotinib. Reproduced from [113] with permission from Wiley-VCH © 2015